Pyelonephritis
4 original drugsPyelonephritis has 4 FDA-approved novel treatments, led by CUBIST PHARMS LLC across 2 drug targets. Explore market leaders, treatments by mechanism, the clinical pipeline, and drug targets below.
Pyelonephritis Market Leaders
Companies with the most FDA-approved novel Pyelonephritis drugs.
Pyelonephritis Clinical Pipeline by Phase
5 industry-sponsored trials across 3 sponsors
Novel Pyelonephritis Drugs by Company (New molecular entities)
4 companies have an FDA-approved novel drug for Pyelonephritis.
Reformulations (7 drugs) Click to expand
Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.
Pyelonephritis Drug Targets
Molecular targets of approved and investigational Pyelonephritis drugs — 2 targets tracked.
Generic Drugs (5 ANDA approved) Click to expand
Generic drugs contain the same active ingredient as the brand-name drug and are approved via ANDA (Abbreviated New Drug Application).
Drug Categories:
- Novel Drugs: NDA Type 1/2 (new molecular entity) or original BLA
- Reformulations: NDA Type 3/5 (new dosage form of existing molecule)
- Biosimilars: BLA-approved biologics highly similar to reference products
- Generics: ANDA-approved copies of small molecule drugs